

Series-27

PHARMACOVIGILANCE UNIT, KMCHIHSR

DRUG SAFETY ALERT

DECEMBER – 2024

Indian Pharmacopoeia Commission (IPC) after the preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database reveals that the following suspected drug is associated with the ADR as given below.

S.NO	SUSPECTED DRUG	INDICATIONS	ADVERSE DRUG REACTION
1	Beta-blockers (Metoprolol, Propranolol, Atenolol)	<p>Metoprolol: For the treatment of essential hypertension in adults, functional heart disorders, migraine prophylaxis, cardiac arrhythmias, prevention of cardiac death and reinfarction after the acute phase of myocardial infarction, stable symptomatic CHF and angina pectoris.</p> <p>Propranolol: For the treatment of cardiac arrhythmias; tachycardia; hypertrophic obstructive cardiac myopathy; pheochromocytoma; thrombosis; management of angina; essential and renal hypertension; prophylaxis of migraine.</p> <p>Atenolol: For the treatment of hypertension, angina pectoris, cardiac arrhythmias.</p>	Hypokalaemia

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the Pharmacovigilance unit, KMCHIHSR via **Email (pharmacovigilance@kmchihsr.edu.in) /Landline No (04226806808).**

Click on the below link to find the list of Monthly Drug Safety Alerts from Mar 2016 to Till date: https://www.ipc.gov.in/images/List_of_Drug_Safety_Alerts_issued_by_PvPI_IPC_till_date.pdf